Company Description
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States.
The company’s lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer.
The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules.
HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 20, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Hing Wong |
Contact Details
Address: 2929 North Commerce Parkway Miramar, Florida 33025 United States | |
| Phone | 954 842 2024 |
| Website | hcwbiologics.com |
Stock Details
| Ticker Symbol | HCWB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001828673 |
| CUSIP Number | 40423R105 |
| ISIN Number | US40423R1059 |
| Employer ID | 82-5024477 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hing C. Wong Ph.D. | Founder, Chief Executive Officer, Director and Secretary |
| Rebecca Byam CPA, M.B.A. | Chief Financial Officer |
| Dr. Peter Rhode Ph.D. | Chief Scientific Officer and Vice President of Clinical Operations |
| Nicole Valdivieso Esq. | Vice President of Legal Affairs |
| Lee D. Flowers | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DRS | [Cover] Draft Registration Statement |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 16, 2025 | EFFECT | Notice of Effectiveness |
| Apr 16, 2025 | 424B3 | Prospectus |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 7, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |